As shown in Fig 6A, genes associated with failure to respond to Bevacizumab in breast cancer patients (Bev Resistance Gene Set#1) or genes upregulated in GBM xenografts upon Bevacizumab resistance (Bev Resistance Gene Set#2) showed significant enrichment in FOXC2-activated genes, but not EMT-associated genes (Fig S6B), consistent with a potential role for FOXC2 in AAT resistance. The gene discussed is FOXC2; the disease is breast cancer.